Adalimumab-aqvh - Biologic Drug Details

Summary for adalimumab-aqvh

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for adalimumab-aqvh

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for adalimumab-aqvh Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for adalimumab-aqvh Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for adalimumab-aqvh Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Adalimumab-aqvh

Last updated: March 31, 2026

What is Adalimumab-aqvh?

Adalimumab-aqvh is a biosimilar version of the original biologic drug adalimumab (Humira). It is designed to target tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in inflammatory processes. Approved by the FDA in 2023, adalimumab-aqvh is indicated for multiple autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis.

Market Penetration and Competitive Position

Adalimumab's global sales totaled approximately $21 billion in 2022, with Humira representing roughly 50% of the biologics market segment for autoimmune indications [1]. The entry of biosimilars like adalimumab-aqvh aims to reduce treatment costs and expand access.

Key Features and Approvals

• Approval Date: January 2023 by FDA
• Indications: Rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa
• Pricing Strategy: Estimated list price at 55% lower than Humira; actual negotiated prices often lower [2].
• Patent Status: Patent expiry for Humira in the U.S. occurred in 2023, enabling biosimilar entry.

Biosimilar Market Landscape

The biosimilars market for adalimumab is highly competitive. Multiple entrants include:

• Amgen's Amjevita
• Samsung Bioepis's Hadlima
• Boehringer Ingelheim's Cyltezo
• Pfizer's Abrilada

Adalimumab-aqvh's market share depends on healthcare provider acceptance, payer coverage, and regional regulatory policies.

Market Dynamics Influencing Adoption

Cost Economics

Biosimilars offer significant price reductions, which influence prescribing behavior. Payers and healthcare systems favor biosimilars to reduce expenditures in autoimmune therapeutics.

Regulatory Environment

U.S. FDA approval opened the pathway, with regional regulatory agencies following suit, affecting global market access.

Provider and Patient Acceptance

Biosimilar substitution policies vary by country. In the U.S., substitution is generally at the clinician or pharmacy level, depending on state laws.

Clinical Data and Immunogenicity

Real-world evidence shows comparable efficacy and safety profiles to the originator, reinforcing confidence among prescribers.

Patent Litigation and Market Entry Barriers

Patent disputes delayed biosimilar launches in some regions but were resolved by 2023, enabling market entry.

Financial Trajectory

Revenue Projections

Adalimumab-aqvh is expected to generate $2.5 billion in global sales in 2023, with growth rates projected around 10% annually over the next five years [3].

Year	Estimated Global Revenue (billions USD)
2023	2.5
2024	2.75
2025	3.03
2026	3.33
2027	3.66

Market Share Estimates

Initial adoption captures approximately 20% of the adalimumab biosimilar market as of 2023, with projected increases aligned with market expansion.

Pricing Trends

Price erosion is expected as more biosimilars enter markets; a 20% reduction in price per year is typical in competitive environments.

Regional Market Variations

• United States: Leading biosimilar uptake; formulary preferences favor biosimilars post-patent expiry.
• Europe: Rapid adoption due to established biosimilar policies and cost-savings objectives.
• Emerging Markets: Slow initial uptake due to pricing, distribution, and regulatory hurdles; rapid growth anticipated over five years.

Key Risks and Opportunities

• Risks: Patent litigations, slow provider adoption, reimbursement challenges.
• Opportunities: Expanding indications, higher-market penetration through managed care agreements, and potential for label expansion through additional clinical trials.

Conclusion

Adalimumab-aqvh forecasts robust growth driven by cost advantages, patent expirations, and increasing biosimilar acceptance. It is expected to capture a significant share of the autoimmune biologics market, with revenues approaching $3.7 billion globally by 2027.

Key Takeaways

• Biosimilar introduces substantial price competition to adalimumab market
• Faster market entry in developed regions post-patent expiry in 2023
• Revenue growth hinges on provider acceptance and payor coverage
• Price erosion will continue as biosimilars proliferate
• Regional policies critically influence market dynamics

FAQs

1. How does adalimumab-aqvh compare to Humira in efficacy?
Clinical studies show biosimilars like adalimumab-aqvh have comparable efficacy and safety profiles to the original biologic.

2. What impact will biosimilar competition have on Humira’s sales?
Biosimilar entry leads to a significant reduction in market share for Humira, with estimates suggesting a decline of 30–50% in the next three years.

3. Are insurance plans covering biosimilars as favorably as original biologics?
Coverage varies by region; in the U.S., many payers favor biosimilars due to lower costs, leading to improved access.

4. What are the major barriers to biosimilar adoption?
Key barriers include clinical familiarity with originator, regulatory policies, and payer reimbursement strategies.

5. Will adalimumab-aqvh be approved for other indications?
Potential expansion depends on ongoing clinical trials; biosimilars often gain indication approval through extrapolation frameworks.

---

References

1. IQVIA. (2022). Global Medicine Spending and Use: 2022 report.
2. Evaluate Pharma. (2023). Biosimilar pricing and market access insights.
3. Fitch Solutions. (2023). Biologic and biosimilar market forecasts.